Novartis has settled a lawsuit brought by Daiichi Sankyo’s Plexxikon subsidiary, paying $180 million to resolve claims that its Tafinlar cancer drug infringed US patents held by the company.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,